Sagimet Biosciences Inc. (Series A) (SGMT) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $9.92 (-4.89% 1D, market cap $735.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGMT ranks #405 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APMD (Apnimed Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $721.9M) and WVE (Wave Life Sciences Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $0 in revenue, -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SGMT currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.94) and Max Pain ($10.42) forces dealer call-delta covering toward $12.02.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Sagimet Biosciences Inc. (Series A) (SGMT) dropped -4.89% to $9.92, trading at 78% of its 52-week range ($4.5 – $11.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regula
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal trial des
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
SGMT pivots denifanstat to acne with Phase 3 data and a funded U.S. registrational trial.
Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SGMT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SGMT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Sagimet Biosciences Inc. (Series A) (SGMT) ranks #405 by composite RQD confidence (45/100, grade D) and #395 by equity capitalization ($735.7M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. GYRE currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SGMT at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SGMT
ACTIVE
Sagimet Biosciences Inc. (Series A) | D | 45/100 | — | — | -35.0% | -4.89% | $735.7M | Benchmark Subject |
| APMD Apnimed Inc. | D | 44/100 | — | — | — | -5.42% | $721.9M | /apmd-vs-sgmt → |
| WVE Wave Life Sciences Inc. | E | 22/100 | — | — | -35.0% | -1.10% | $715.9M | /wve-vs-sgmt → |
| GYRE Gyre Therapeutics Inc. | D | 47/100 | 72.3x | 95.4% | 25.4% | -28.94% | $714.8M | /gyre-vs-sgmt → |
| ANNX Annexon Inc. | E | 30/100 | — | — | -35.0% | +1.00% | $760.2M | /annx-vs-sgmt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$51.0M, operating cash flow of -$45.6M, and free cash flow of -$45.6M (-7.6% YoY). On the balance sheet, SGMT closed FY2025 with $116.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$51.0M | -$45.6M | -$45.6M | $116.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$45.6M | -$42.4M | -$42.4M | $160.3M | — |
| FY2023 (FY) | 2023-12-31 | $2.0M | -$27.9M | -$23.8M | -$23.8M | — | — |
As of 2026-11-02, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $9.92 (-4.89% 1D, market cap $735.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGMT ranks #405 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, APMD (Apnimed Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $721.9M) and WVE (Wave Life Sciences Inc.) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).
Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $0 in revenue, -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SGMT last traded at $9.92 (-4.89% on volume of 989,160 shares), positioning the stock -0.20% below its 50-day simple moving average ($9.94) and +31.91% above its 200-day simple moving average ($7.52). Across its 52-week range of $4.50 to $11.45, SGMT sits at the 78.0% percentile with a 14-day RSI of 57.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.68 to $11.16).
Why SGMT Stock dropped -4.89% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SGMT scores 45 out of 100, earning a "D" grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
Taken together, the rating signals that the stock's valuation is not supported by current cash generation. Upside would depend on factors outside the reported cash engine, while the distribution warning and weak insider signals argue for caution. The valuation tradeoff is that a $735.7M market capitalization rests on pre-revenue losses, making the investment case highly sensitive to future cash burn and funding conditions.
Per the SEC financials and profile, Sagimet Biosciences Inc. (Series A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is $0.0M for FY 2025 and FY 2024, with $2.0M reported for FY 2023. Per the profile, the company has a market capitalization of $0.7B. Source data does not describe its specific products, customers, or monetization model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-56.9M | $-51.0M | N/A | $-45.6M | $35.0M | N/A |
| FY 2024 | $0.0M | $-54.5M | $-45.6M | N/A | $-42.4M | $75.8M | N/A |
| FY 2023 | $2.0M | $-30.7M | $-27.9M | N/A | $-23.8M | N/A | N/A |
Per the SEC financials, the company reported operating losses in every period shown, with net losses of $-51.0M in FY 2025 and $-45.6M in FY 2024. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash declined from $75.8M to $35.0M between FY 2024 and FY 2025, and debt is not available in source data for any period.
Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data.
Real-time company headlines, analyst actions, and sector developments for Sagimet Biosciences Inc. (Series A) (SGMT) • Click "Debate This Headline" to argue it in the Roar Pit below
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regula
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal trial des
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
SGMT pivots denifanstat to acne with Phase 3 data and a funded U.S. registrational trial.
Sagimet Biosciences Inc. (SGMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn
Welcome to the SGMT (Sagimet Biosciences Inc. (Series A)) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SGMT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sagimet Biosciences Inc. (Series A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SGMT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.43 (52-wk range $4.50 - $11.45), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).